Hizal, M; Bilgin, B; Paksoy, N; Acikgoz, O; Sezer, A; Gurbuz, M; Ak, N; Yucel, S; Ayhan, M; Erol, C; Demirkiran, A; Mandel, NM; Shbair, A; Gokmen, I; Basoglu, T; Paydas, S; Demiray, AG; Iriagac, Y; Sakalar, T; Zeynelgil, E; Tatli, AM; Bahceci, A; Guven, DC; Caner, B; Can, A; Gulmez, A; Karakas, Y; Yalcin, B; Demirkazik, A; Bilici, A; Aydiner, A; Yumuk, PF; Sendur, MAN
(2022)
Introduction Osimertinib, an irreversible third-generation EGFR-TKI, is the standard of care for second-line treatment of T790M-mutant advanced NSCLC patients whose disease progressed after first-line EGFR-TKI therapy. In ...